SER BERNARD BUNGUBUNG: Open Payments
NPI 1467223008 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,491 in 90 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $2,302 · 2025 $2,491
Food & beverage: $2,491
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $1,073 |
| Neurocrine BioSciences, Inc. | 6 | $217 |
| Otsuka America Pharmaceutical, Inc. | 6 | $213 |
| Janssen Biotech, Inc. | 4 | $179 |
| ARGENX US, INC. | 10 | $158 |
| Eisai Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $111 |
| Novartis Pharmaceuticals Corporation | 4 | $98 |
| UCB, Inc. | 3 | $81 |
| PFIZER INC. | 2 | $48 |
Products named: QULIPTA, UBRELVY, INGREZZA, REXULTI, BOTOX, VYVGART HYTRULO, Leqembi, HYQVIA.
Industry payments across NV — which companies pay providers there.
